Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Heart failure is a major cause of morbidity and mortality in type 2 diabetes. Type 2 diabetes contributes to the development of heart failure through a variety of mechanisms, including disease-specific myocardial structural, functional and metabolic changes. This review will focus on the contemporary contributions of state of the art non-invasive technologies to our understanding of diabetic cardiomyopathy, including data on cardiac disease phenotype, cardiac energy metabolism and energetic deficiency, ectopic and visceral adiposity, diabetic liver disease, metabolic modulation strategies and cardiovascular outcomes with new classes of glucose-lowering therapies.

Original publication

DOI

10.1530/EJE-17-0724

Type

Journal article

Journal

Eur J Endocrinol

Publication Date

04/2018

Volume

178

Pages

R127 - R139

Keywords

Animals, Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies, Energy Metabolism, Humans, Hypoglycemic Agents